Prognostic significance of c-Met expression in glioblastomas

Authors

  • Doo-Sik Kong MD, PhD,

    1. Department of Neurosurgery, Samsung Medical Center and Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine, Seoul, Korea
    Search for more papers by this author
    • The first 2 authors contributed equally to this article.

  • Sang-Yong Song MD, PhD,

    1. Department of Pathology, Samsung Medical Center and Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine, Seoul, Korea
    Search for more papers by this author
    • The first 2 authors contributed equally to this article.

  • Duk-Hwan Kim MD,

    1. Department of Molecular Cell Biology, Samsung Medical Center and Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine, Seoul, Korea
    Search for more papers by this author
  • Kyeung Min Joo MD, PhD,

    1. Department of Neurosurgery, Samsung Medical Center and Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine, Seoul, Korea
    Search for more papers by this author
  • Jin-San Yoo PhD,

    1. The Therapeutic Antibody Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Korea
    Search for more papers by this author
  • Jong Sung Koh PhD,

    1. Center for Anti-Cancer Research, Korea Research Institute of Chemical Technology, Daejeon, Korea
    Search for more papers by this author
  • Seung Myung Dong PhD,

    1. Research Institute, National Cancer Center, Goyang, Gyeonggi, Korea
    Search for more papers by this author
  • Yeon-Lim Suh MD, PhD,

    1. Department of Pathology, Samsung Medical Center and Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine, Seoul, Korea
    Search for more papers by this author
  • Jung-Il Lee MD, PhD,

    1. Department of Neurosurgery, Samsung Medical Center and Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine, Seoul, Korea
    Search for more papers by this author
  • Kwan Park MD, PhD,

    1. Department of Neurosurgery, Samsung Medical Center and Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine, Seoul, Korea
    Search for more papers by this author
  • Jong Hyun Kim MD, PhD,

    1. Department of Neurosurgery, Samsung Medical Center and Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine, Seoul, Korea
    Search for more papers by this author
  • Do-Hyun Nam MD, PhD

    Corresponding author
    1. Department of Neurosurgery, Samsung Medical Center and Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine, Seoul, Korea
    • Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Ilwon-dong, Kangnam-gu, Seoul 135-710, South Korea===

    Search for more papers by this author
    • Fax: (011) 822-3410-0048


Abstract

BACKGROUD:

The authors investigated whether expression of c-Met protein in glioblastomas is associated with overall survival and biologic features representing tumor invasiveness in patients with glioblastomas.

METHODS:

Paraffin-embedded specimens of glioblastomas from 62 patients treated in a single institution were assessed by immunohistochemical (IHC) analysis of c-Met expression. On the basis of the clinical data for these patients, the association between c-Met expression and clinicobiologic features representing tumor invasiveness was analyzed.

RESULTS:

c-Met overexpression was detected in 29.0% (18 of 62) of glioblastomas. In patients with c-Met overexpression, the median survival was 11.7 months (95% confidence interval [95% CI], 9.9 months-13.5 months), compared with a median survival of 14.3 months (95% CI, 7.6 months-21.0 months) for patients whose tumors had no or little expression of c-Met (P = .031). On the radiographic analysis, 9 of 18 patients (50%) with tumors overexpressing c-Met demonstrated invasive and multifocal lesions on the initial magnetic resonance images, whereas only 9 of 44 patients (20.5%) with tumors that expressed no or little c-Met demonstrated these features (P = .030). Using immunohistochemistry, we also found a significant association between c-Met expression and matrix metalloproteinase-2,-9 (P = .020 and P = .013). Furthermore, Myc overexpression was found to be closely correlated with c-Met overexpression on IHC analysis (P = .004).

CONCLUSIONS:

The authors suggest that c-Met overexpression is associated with shorter survival time and poor treatment response in glioblastomas, the mechanism for which is elevated tumor invasiveness on the molecular and clinical phenotypes. This implies that more effective therapeutic strategies targeting c-Met receptors may have important clinical implication. Cancer 2009. © 2008 American Cancer Society.

Ancillary